AU6007900A - Azetidine carboxamide derivatives for the treatment of cns disorders - Google Patents

Azetidine carboxamide derivatives for the treatment of cns disorders

Info

Publication number
AU6007900A
AU6007900A AU60079/00A AU6007900A AU6007900A AU 6007900 A AU6007900 A AU 6007900A AU 60079/00 A AU60079/00 A AU 60079/00A AU 6007900 A AU6007900 A AU 6007900A AU 6007900 A AU6007900 A AU 6007900A
Authority
AU
Australia
Prior art keywords
treatment
cns disorders
carboxamide derivatives
azetidine carboxamide
azetidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU60079/00A
Inventor
Allan Fletcher
Nathaniel Julius Monck
Mike Frederick Snape
Kelly Jean Stanhope
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Ltd filed Critical Vernalis Research Ltd
Publication of AU6007900A publication Critical patent/AU6007900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU60079/00A 1999-07-23 2000-07-21 Azetidine carboxamide derivatives for the treatment of cns disorders Abandoned AU6007900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9917385.8A GB9917385D0 (en) 1999-07-23 1999-07-23 Chemical compounds-I
GB9917385 1999-07-23
PCT/GB2000/002840 WO2001007043A1 (en) 1999-07-23 2000-07-21 Azetidine carboxamide derivatives for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
AU6007900A true AU6007900A (en) 2001-02-13

Family

ID=10857863

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60079/00A Abandoned AU6007900A (en) 1999-07-23 2000-07-21 Azetidine carboxamide derivatives for the treatment of cns disorders

Country Status (5)

Country Link
EP (1) EP1196166A1 (en)
JP (1) JP2003505418A (en)
AU (1) AU6007900A (en)
GB (1) GB9917385D0 (en)
WO (1) WO2001007043A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9917386D0 (en) * 1999-07-23 1999-09-22 Cerebrus Ltd Chemical compounds-II
JOP20190072A1 (en) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors
TW201938164A (en) 2018-01-08 2019-10-01 瑞士商赫孚孟拉羅股份公司 New heterocyclic compounds
CR20230115A (en) * 2020-09-03 2023-04-11 Hoffmann La Roche HETEROCYCLIC COMPOUNDS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4505907A (en) * 1982-09-02 1985-03-19 A. H. Robins Company, Inc. N-Formyl and N-hydroxymethyl-3-phenoxy-1-azetidinecarboxamides
IE58943B1 (en) * 1985-02-28 1993-12-01 Robins Co Inc A H 3-Aryloxy-azetidine-carboxamides
GB9801501D0 (en) * 1998-01-23 1998-03-18 Cerebrus Ltd Chemical compounds - II

Also Published As

Publication number Publication date
EP1196166A1 (en) 2002-04-17
JP2003505418A (en) 2003-02-12
GB9917385D0 (en) 1999-09-22
WO2001007043A1 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
HUP0102295A3 (en) Benzamide derivatives for the treatment of diseases mediated by cytokines
HUP0102367A3 (en) Benzamide derivatives for the treatment of diseases mediated by cytokines
AU8187701A (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU6910600A (en) Methods for the treatment of mental disorders
AU5908300A (en) Prevention and treatment of amyloid-associated disorders
AU1356201A (en) Treatment of hyperproliferative disorders
AU2002215047A1 (en) Isoquinoline derivatives useful in the treatment of cns disorders
AU7388101A (en) Indole derivatives useful for the treatment of cns disorders
AU6007900A (en) Azetidine carboxamide derivatives for the treatment of cns disorders
IL153605A0 (en) Indole derivatives useful for the treatment of cns disorders
AU2003278084A1 (en) Benzo(d)azepine derivatives for the treatment of neurological and psychiatric disorders
AU3899100A (en) Treatment of hyperactivity disorders
AU1028501A (en) Isoquinoline and quinazoline derivatives for the treatment of cns disorders
CZ20011872A3 (en) Isonipecotamides for the treatment of integrin-mediated disorders
IL153254A0 (en) Indole derivatives useful for the treatment of cns disorders
AU2080201A (en) Treatment of addiction disorders
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
AU8339301A (en) Compounds for the treatment of addictive disorders
AU2002221566A1 (en) Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
SI1468686T1 (en) S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders
AU2003239967A1 (en) Compound for the treatment of cns disorders
AU2003243214A1 (en) Salts of bis-arylsulfones for the treatment of cns disorders
AU7521598A (en) Aralkoxy-morphinan derivatives for treatment of cns disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase